The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.
Academic rigor, journalistic flair
Articles on Prescription drug costs
Displaying all articles
The pharma industry claims lower prescription drug prices will mean less access to new medication for Canadians. It’s an old threat that pits profits against patients’ rights to affordable drugs.
A new law will let Medicare bargain for the first time. But a health policy scholar explains why it’s unlikely to make much of a difference in how much seniors – or anyone else – pays for their meds.
About 1 in 4 Americans with diabetes who need insulin struggle to pay for this lifesaving drug.
Any pharmacare plan that aims to remove financial barriers to treatment and eliminate inequities should prioritize those who face the highest out-of-pocket drug costs, such as people with disabilities.
Presidential candidates and the current president have all talked about ways to lower drug costs, but experts know it is going to take more than politics to change how drugs are priced in the US.
Presidential candidates have been proposing plans to expand health coverage, lower prescription drug costs and make hospital bills more transparent. But few get to the real problem. Here’s why.
Top contributors
-
Joel Lexchin is a Friend of The Conversation.Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor of Public Health, Texas A&M University
-
Associate Professor of Health Behavior & Health Education, University of Michigan
-
Professor, School of Rehabilitation Therapy, Queen's University, Ontario
-
Associate Professor of Surgery and Public Policy, University of Virginia
-
Associate Professor & Program Director, Public Health Policy & Management, University of Arizona
-
Research Coordinator, Centre for Health Services and Policy Research and School of Rehabilitation Therapy, Queen's University, Ontario
-
Assistant Professor of Medicine, University of Pittsburgh
-
Director of the Health Law Institute at the Schulich School of Law, Dalhousie University
-
Professor of Economics, University of Calgary
-
Associate professor, School of Public Health, University of Alberta
-
Professor of Health Economics, Queen's University Belfast
-
Professor, School of Population and Public Health, University of British Columbia
